I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $16.92
    +0.03 (+0.18%)

    Market Cap: $1.31B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +11.09%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.56
    Range$0.53 - $0.59
    11 analysts
    EPS Revisions
    4
    0
    7d
    3
    5
    30d
    EPS Estimate Drift
    90d ago$0.57+1.0%
    60d ago$0.56-0.5%
    30d ago$0.56-0.5%
    7d ago$0.57+1.1%
    Current$0.56
    Revenue Consensus
    $416M
    Range$411M - $422M
    11 analysts
    Dec 31, 2026
    EPS Consensus$1.01
    Range$0.96 - $1.05
    12 analysts
    Revenue Consensus
    $459M
    Range$451M - $470M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.01---
    Sep 26EST
    		-$0.56---
    Jun 26
    		$0.56$0.48+16.67%Beat+24.4%
    Mar 26
    		$0.54$0.40+35.00%Beat+31.7%
    Dec 25
    		$0.83$0.79+5.06%Beat-14.4%
    Sep 25
    		$0.54$0.43+25.58%Beat+31.7%
    Jun 25
    		$0.45$0.43+4.65%Beat-28.6%
    Mar 25
    		$0.41$0.43-4.65%Miss-25.5%
    Dec 24
    		$0.97$0.86+13.40%Beat+9.0%
    Sep 24
    		$0.41$0.39+5.13%Beat-46.1%
    Jun 24
    		$0.63$0.62+1.61%Beat-11.3%
    Mar 24
    		$0.55$0.55+0.00%Beat-25.7%
    Dec 23
    		$0.89$0.90-1.11%Miss-5.3%
    Sep 23
    		$0.76$0.78-2.56%Miss-11.6%
    Jun 23
    		$0.71$0.57+24.56%Beat-13.4%
    Mar 23
    		$0.74$0.74+0.00%Beat+0.0%
    Dec 22
    		$0.94$0.90+4.44%Beat+11.9%
    Sep 22
    		$0.86$0.72+19.44%Beat+0.0%
    Jun 22
    		$0.82$0.80+2.50%Beat+3.8%
    Mar 22
    		$0.74$0.68+8.82%Beat+7.2%
    Dec 21
    		$0.84$0.83+1.20%Beat+0.0%
    Sep 21
    		$0.86$0.72+19.44%Beat+7.5%
    Jun 21
    		$0.79$0.66+19.70%Beat+139.4%
    Mar 21
    		$0.69$0.57+21.05%Beat+43.7%
    Dec 20
    		$0.84$0.73+15.07%Beat+23.5%
    Sep 20
    		$0.80$0.54+48.15%Beat+17.6%
    Jun 20
    		$0.33$0.15+120.00%Beat-54.8%
    Mar 20
    		$0.48$0.63-23.81%Miss-26.2%
    Dec 19
    		$0.68$0.67+1.49%Beat+4.6%
    Sep 19
    		$0.68$0.66+3.03%Beat+15.3%
    Jun 19
    		$0.73$0.66+10.61%Beat+21.7%
    Mar 19
    		$0.65$0.61+6.56%Beat+12.1%
    Dec 18
    		$0.65$0.62+4.84%Beat+1.6%
    Sep 18
    		$0.59$0.59+0.00%Beat+31.1%
    Jun 18
    		$0.60$0.60+0.00%Beat+33.3%
    Mar 18
    		$0.58$0.49+18.37%Beat+48.7%
    Dec 17
    		$0.64$0.56+14.29%Beat+23.1%
    Sep 17
    		$0.45$0.47-4.26%Miss-4.3%
    Jun 17
    		$0.45$0.45+0.00%Beat-
    Mar 17
    		$0.39$0.38+2.63%Beat-
    Dec 16
    		$0.52$0.52+0.00%Beat-
    Sep 16
    		$0.47$0.44+6.82%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio6.85EV/EBITDA12.58x
    Price/FCF50.69xFCF Yield1.97%
    Profitability
    Profit Margin-0.44%Operating Margin9.62%
    ROE-0.70%ROIC2.54%
    Financial Health
    Debt/Equity1.79xInterest Coverage0.81x
    Current Ratio3.60xQuick Ratio2.11x
    Trading Statistics
    Beta1.21Avg Volume620.75K
    52-Week High$20.4952-Week Low$8.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.91
    SMA 20$17.26
    SMA 50$17.90
    SMA 200$13.69
    EMA 10$17.00
    EMA 20$17.24
    EMA 50$17.20
    EMA 200$15.15

    MACD

    Line: -0.29Signal: -0.25Hist: -0.04

    ADX

    ADX: 15.9+DI: 17.1-DI: 22.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down8.0
    PSAR$18.84

    Bollinger Bands

    Upper Band$18.27
    Lower Band$16.24
    %B Position1174%(Upper)
    Band Width0.33

    RSI (14-Day)

    Neutral
    44.6

    Momentum Oscillators

    Stoch %K22.0
    Stoch %D21.1
    Williams %R-76.5
    ROC (10d)-4.2%
    Momentum-0.74
    CCI (20d)-86.0
    MFI (14d)31.9

    Volatility Measures

    ATR (14d)$0.74(4.4%)
    StdDev (20d)0.51
    Hist Vol31.3%(Moderate)

    Volume Flow

    VWAP$16.78
    OBV4.8M
    AD Line-9.7M
    CMF (20d)-0.230

    Volume Metrics

    Avg Vol (20d)587.8K
    Vol Ratio1.0x
    VWMA (20d)$17.28

    Pivot Points

    R3$17.65
    R2$17.49
    R1$17.19
    Pivot Point$17.03
    S1$16.73
    S2$16.57
    S3$16.27

    Advanced Oscillators

    TSI-10.53
    Ultimate Osc47.9
    KST-58.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$418.76M$391.92M$434.93M$402.06M$415.61M$382.65M$442.65M$380.83M$418.18M$368.87M$397.04M$382.42M
    Cost of Revenue$199.02M$174.94M$214.06M$195.07M$206.27M$188.22M$193.57M$180.60M$192.26M$162.04M$170.55M$164.08M
    Gross Profit$219.74M$216.98M$220.87M$206.99M$209.33M$194.43M$249.07M$200.24M$225.92M$206.83M$226.49M$218.34M
    Operating Expenses$200.46M$205.51M$197.82M$195.23M$722.01M$209.93M$213.45M$208.39M$228.95M$202.87M$190.45M$191.75M
    R&D$24.25M$23.50M$24.79M$22.46M$27.00M$24.73M$31.21M$27.43M$29.77M$26.96M$24.28M$26.60M
    SG&A$172.44M$178.24M$169.27M$169.05M$179.89M$181.50M$178.52M$177.19M$195.47M$165.80M$163.13M$161.95M
    Operating Income$19.29M$11.47M$23.04M$11.76M$-512,674,000$-15,497,000$35.63M$-8,150,000$-3,029,000$3.96M$36.05M$26.59M
    Interest Income$4.27M$4.11M$4.36M$4.98M$4.71M$4.42M$4.89M$5.05M$5.06M$5.04M$4.55M$4.61M
    Interest Expense$22.99M$22.46M$23.67M$22.73M$21.04M$18.82M$18.98M$19.37M$18.65M$13.62M$13.75M$13.06M
    Income Before Tax$4.74M$-2,409,000$4.31M$-6,824,000$-530,952,000$-30,036,000$22.54M$-20,362,000$-15,185,000$-5,230,000$28.86M$18.61M
    Income Tax Expense$262,000$2.21M$6.01M$-1,420,000$-46,879,000$-4,743,000$3.11M$-9,667,000$-2,783,000$-1,949,000$9.02M$-888,000
    Net Income$4.48M$-4,617,000$-1,704,000$-5,404,000$-484,073,000$-25,293,000$19.43M$-10,695,000$-12,402,000$-3,281,000$19.83M$19.50M
    EBITDA$62.63M$55.38M$63.07M$50.76M$-475,038,000$22.93M$75.62M$31.26M$36.65M$35.32M$70.48M$59.04M
    EBIT$23.47M$15.95M$23.62M$10.92M$-514,620,000$-15,641,000$36.63M$-6,038,000$-1,592,000$3.35M$38.06M$27.06M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IART

    News

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Integra LifeSciences (IART) Investors of Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys

    Hagens Berman is reminding Integra LifeSciences (IART) investors of a pending securities fraud class action lawsuit. The litigation focuses on Integra's alleged false and misleading statements regarding FDA violations at its Boston Facility, which led to a product recall and production halt. Investors who suffered substantial losses are encouraged to contact Hagens Berman to discuss their legal rights.

    TMX Newsfile•8/22/26•
    Bearish

    Is IART Still Attractive as Its Low Valuation Meets Execution Risks?

    Integra LifeSciences Holdings Corp. (IART) trades at a significant valuation discount compared to its industry and market benchmarks, driven by recent margin gains and improved operating execution. However, the company faces challenges including modest revenue growth, elevated leverage, and unresolved regulatory remediation with the FDA. Despite these risks, Integra's operational improvements and cost savings offer support for its earnings outlook, making execution crucial for its investment appeal.

    TradingView•8/19/26•
    Neutral

    Integra LifeSciences /US Number of Employees 2026 | Employee Count & Headcount Data

    Integra LifeSciences Holdings Corp. (IART) had approximately 4,344 employees worldwide as of March 2026, representing a 0.6% decline from 2023. The company is actively hiring, with 272 active job postings in 2026, though this is a significant decline from previous years. The workforce is concentrated in North America, and overall employee sentiment is reported as negative and declining.

    Revelio Labs•8/14/26•
    Bearish

    Assenagon Asset Management S.A. Reduces Position in Integra LifeSciences Holdings Corporation $IART

    Assenagon Asset Management S.A. significantly reduced its stake in Integra LifeSciences Holdings Corporation by 66.3% in the second quarter of 2026, selling over 276,000 shares. Despite this, other institutional investors like Rubric Capital Management LP and Paradigm Capital Management Inc. NY increased their holdings. The stock opened up 4.9% at $18.24 following a beat on quarterly EPS and revenue, with analysts maintaining a cautious "Reduce" average rating but an Argus upgrade to "Buy."

    MarketBeat•8/14/26•
    Neutral

    Paradigm Capital discloses 4.42% Integra LifeSciences (IART) stake with sole voting control

    Paradigm Capital Management, Inc. has reported an amended stake in Integra LifeSciences Holdings Corp (IART), disclosing beneficial ownership of 3,439,098 shares, which represents 4.42% of the outstanding common stock. The New York S corporation maintains sole voting and dispositive power over all these shares. This filing characterizes their holding as ownership of 5 percent or less of the class, aligning with regulatory reporting thresholds.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About IART

    Does IART pay dividends?
    Integra LifeSciences Holdings (IART) has a dividend payment track record. See the IART dividend history page for its current payment status, yield, and streaks.
    What is IART's P/E ratio?
    Integra LifeSciences Holdings has a price-to-earnings (P/E) ratio of 6.85.
    What is IART's market cap?
    Integra LifeSciences Holdings (IART) has a market capitalization of $1.31B with a current stock price of $16.92.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In